ISPO

Published in Cancer Detection and Prevention 2000; 24(Supplement 1).

Demonstration of p53 autoantibodies in sera indicates a fatal outcome in patients suffering from transitional cell carcinoma of urinary bladder

W Hindermann MD 1, H Wunderlich MD 2, U Junker MD 3, A Berndt MD 1, H Kosmehl MD 1

Institute of Pathology, 1 Dept Urology, 2 Institute of Clinical Immunology, 3 Friedrich Schiller University, Jena, Germany, hindermann@bach.med.uni-jena.de

AIMS: Analysis of immunohistochemical p53 expression and occurrence of p53 autoantibodies in sera in relation to tumor grade, stage and patient outcome. METHODS: 69 patients with invasive or non-invasive transitional cell carcinoma (TCC) of the urinary bladder, follow up period with an average of 23 month. p53 immunohistochemistry was performed with the MAB DO-7 and APAAP technique. Detection of p53 autoantibodies in serum by an enzyme linked immuno-sorbent assay. 10 sera from healthy volunteers were used as control. Statistical analysis of the associations by Kruskal-Wallis test. RESULTS: In 8 out of 69 patients (11,6 %) with invasive TCC serum p53 autoantibodies could be demonstrated (3 patients with G2, 5 patients with G3). All patients with p53 autoantibodies showed an immunohistochemically p53 overexpression. No significant association could be established between p53 autoantibodies and tumor grade. 6 of 8 patients (75 %) positive for p53 autoantibodies died within 32 month. CONCLUSIONS: First, the demonstration of p53 autoantibodies in transitional cell carcinoma of the urinary bladder cancer is a rare phenomenon and second, always associated with an immunohistochemical overexpression of p53 and third, it indicates an invasive tumor growth. The demonstration of p53 serum autoantibodies are suggested as a marker of invasive TCC behavior associated with rapid tumor progression and fatal outcome.

KEY WORDS: p53 autoantibodies, transitional cell carcinoma, urinary bladder, fatal outcome.

For more information, contact hindermann@bach.med.uni-jena.de

Paper presented at the International Symposium on Impact of Biotechnology on Cancer Diagnostic & Prognostic Indicators; Geneva, Switzerland; October 28 - 31, 2000; in the section on prognostic markers.

http://www.cancerprev.org/Journal/Issues/24/101/405/3559